Your browser doesn't support javascript.
loading
Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites.
Lee, Eunok; von Stockenstrom, Susanne; Morcilla, Vincent; Odevall, Lina; Hiener, Bonnie; Shao, Wei; Hartogensis, Wendy; Bacchetti, Peter; Milush, Jeffrey; Liegler, Teri; Sinclair, Elizabeth; Hatano, Hiroyu; Hoh, Rebecca; Somsouk, Ma; Hunt, Peter; Boritz, Eli; Douek, Daniel; Fromentin, Remi; Chomont, Nicolas; Deeks, Steven G; Hecht, Frederick M; Palmer, Sarah.
Afiliação
  • Lee E; The Westmead Institute for Medical Research, University of Sydney, Westmead, New South Wales, Australia eunok.lee@sydney.edu.au.
  • von Stockenstrom S; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Morcilla V; The Westmead Institute for Medical Research, University of Sydney, Westmead, New South Wales, Australia.
  • Odevall L; Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Hiener B; The Westmead Institute for Medical Research, University of Sydney, Westmead, New South Wales, Australia.
  • Shao W; Advanced Biomedical Computing Center, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
  • Hartogensis W; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Bacchetti P; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA.
  • Milush J; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Liegler T; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Sinclair E; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Hatano H; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Hoh R; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Somsouk M; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Hunt P; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Boritz E; Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Douek D; Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Fromentin R; Centre de Recherche du CHUM and Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, Canada.
  • Chomont N; Centre de Recherche du CHUM and Department of Microbiology, Infectiology and Immunology, Université de Montréal, Montreal, Canada.
  • Deeks SG; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Hecht FM; Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • Palmer S; The Westmead Institute for Medical Research, University of Sydney, Westmead, New South Wales, Australia.
J Virol ; 94(3)2020 01 17.
Article em En | MEDLINE | ID: mdl-31723024
Understanding the impact of antiretroviral therapy (ART) duration on HIV-infected cells is critical for developing successful curative strategies. To address this issue, we conducted a cross-sectional/inter-participant genetic characterization of HIV-1 RNA from pre- and on-therapy plasmas and HIV-1 DNA from CD4+ T cell subsets derived from peripheral blood (PB), lymph node (LN), and gut tissues of 26 participants after 3 to 17.8 years of ART. Our studies revealed in four acute/early participants who had paired PB and LN samples a substantial reduction in the proportion of HIV-infected cells per year on therapy within the LN. Extrapolation to all 12 acute/early participants estimated a much smaller reduction in the proportion of HIV-1-infected cells within LNs per year on therapy that was similar to that in the participants treated during chronic infection. LN-derived effector memory T (TEM) cells contained HIV-1 DNA that was genetically identical to viral sequences derived from pre- and on-therapy plasma samples. The proportion of identical HIV-1 DNA sequences increased within PB-derived TEM cells. However, the infection frequency of TEM cells in PB was stable, indicating that cellular proliferation that compensates for T cell loss over time contributes to HIV-1 persistence. This study suggests that ART reduces HIV-infected T cells and that clonal expansion of HIV-infected cells maintains viral persistence. Importantly, LN-derived TEM cells are a probable source of HIV-1 genomes capable of producing infectious HIV-1 and should be targeted by future curative strategies.IMPORTANCE HIV-1 persists as an integrated genome in CD4+ memory T cells during effective therapy, and cessation of current treatments results in resumption of viral replication. To date, the impact of antiretroviral therapy duration on HIV-infected CD4+ T cells and the mechanisms of viral persistence in different anatomic sites is not clearly elucidated. In the current study, we found that treatment duration was associated with a reduction in HIV-infected T cells. Our genetic analyses revealed that CD4+ effector memory T (TEM) cells derived from the lymph node appeared to contain provirus that was genetically identical to plasma-derived virions. Moreover, we found that cellular proliferation counterbalanced the decay of HIV-infected cells throughout therapy. The contribution of cellular proliferation to viral persistence is particularly significant in TEM cells. Our study emphasizes the importance of HIV-1 intervention and provides new insights into the location of memory T cells infected with HIV-1 DNA, which is capable of contributing to viremia.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Antirretrovirais / Duração da Terapia Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Humans Idioma: En Revista: J Virol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Infecções por HIV / HIV-1 / Antirretrovirais / Duração da Terapia Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Adolescent / Child / Child, preschool / Humans Idioma: En Revista: J Virol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália